Press Kit
Press & Partner Resources
Downloadable assets for journalists, partners, and investors. Whitepaper is generated live from current data — always reflects the latest metrics.
Whitepaper
MolForge Whitepaper (4-page PDF)
One-page summary + Technology + Validation & Evidence Gates + Target Portfolio + Contact. Generated client-side from live data on this site — numbers always current.
- • Page 1: Executive summary + key metrics
- • Page 2: Technology stack (MolForge-Gen, ROBOGATE, CP, Boltz-2)
- • Page 3: Three Evidence Gates with current status
- • Page 4: Target portfolio (TYK2, TNIK, CDK4/6) + contact
Note: an earlier static April 2026 PDF has been retired — it contained figures since corrected (conformal intervals are provisional/uncalibrated; the “TYK2” dataset was JAK-family/JAK3-seeded and TYK2-selectivity is unproven). Use the “Download Whitepaper PDF” button above, which is generated live from this site’s latest data and always reflects the current, corrected numbers.
Live Numbers (Snapshot)
Fact Sheet
Quick Reference
Company
DigitalBiology Co., Ltd.
Business Reg.
752-88-03445
Headquarters
Gangnam-gu, Seoul, Korea
CEO
Heonjeong Cho — hj@molforgeai.com
CTO
Jewoo Yom — jwyom@molforgeai.com
Patent
KIPO 10-2026-0057732 (ROBOGATE method)
Targets
TYK2, TNIK, CDK4, CDK6, EGFR
Indications
Autoimmune, Oncology, Obesity, IPF
Stage
Gate A passed; Gate B (CRO) in progress
Partnership
NDA-based evaluation; Series A-B biotech / pharma R&D
Web
https://www.molforgeai.com
Press inquiries
contact@molforgeai.com
Company Boilerplate
MolForge is the AI drug discovery platform built by DigitalBiology Co., Ltd. Built on the proprietary MolForge-Gen molecular transformer (25.4M parameters, trained on 1.6M drug-like molecules), MolForge maps the failure boundary of chemical space — identifying exactly which structural modifications cause ADMET failures before any synthesis. The platform integrates Boltz-2 structure prediction, ADMET-AI property scoring, and proprietary Conformal Prediction uncertainty quantification into a fully automated 24/7 pipeline. As of April 2026, 68,530 ADMET-validated compounds have been generated across TYK2 (autoimmune), CDK4/6 (oncology), and TNIK (oncology + obesity, first-in-class opportunity).